- Open Access
Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody
Alzheimer's Research & Therapy volume 14, Article number: 70 (2022)
Correction: Alz Res Therapy 13, 80 (2021)
Following the publication of the original article  files for Supplementary Appendices A and B were not included in the publication of the original article.
Supplementary Appendix A: Study Protocol (BAN2401-G000-201--protocol.pdf)
Supplementary Appendix B: Simulation Plan (simulation plan.pdf)
The original article  has been updated.
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy. 2021;13:80 https://doi.org/10.1186/s13195-021-00813-8.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Swanson, C.J., Zhang, Y., Dhadda, S. et al. Correction: A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody. Alz Res Therapy 14, 70 (2022). https://doi.org/10.1186/s13195-022-00995-9